MorphoSys AG (NASDAQ:MOR) and development partners Galapagos NV (NASDAQ:GLPG) and Novartis Pharma AG (NYSE:NVS) have decided to stop development of MOR106 for atopic dermatitis after an interim analysis of a Phase 2 study showed a low probability of success. All studies will be terminated.
MOR and GLPG jointly discovered the IL-17C inhibitor while Novartis owned exclusive development and commercialization rights under a September 2018 agreement.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.